Table 1.
Summary of baseline characteristics for individual studies
| Study | Background regimen | Comparators | Mean baseline values
|
|||||
|---|---|---|---|---|---|---|---|---|
| Age (years) | Duration of diabetes (years) | BMI (kg/m2) | Weight (kg) | HbA1c (%) | FPG (mg/dL) | |||
| T2DM | ||||||||
| EDITION 1 (Riddle et al30) 6 month |
Basal insulin + mealtime insulin | Gla-300 | 60.1 | 15.6 | 36.6 | 106.2 | 8.15 | 158.3 |
| Gla-100 | 59.8 | 16.1 | 36.6 | 106.4 | 8.16 | 160.7 | ||
| All | 60.0 | 16.0 | 36.6 | 106.3 | 8.15 | 160.0 | ||
| EDITION 2 (Yki Jarvinen et al37) 6 month |
Basal insulin + OAD | Gla-300 | 57.9 | 12.7 | 34.8 | 98.7 | 8.26 | 148.3 |
| Gla-100 | 58.5 | 12.5 | 34.8 | 98.0 | 8.22 | 142.0 | ||
| All | 58.2 | 13.0 | 34.8 | 98.4 | 8.24 | 145.0 | ||
| EDITION 3 (Bolli et al38) 6 month |
Insulin naïve + OAD | Gla-300 | 58.2 | 10.1 | 32.8 | 95.1 | 8.49 | 178.7 |
| Gla-100 | 57.2 | 9.6 | 33.2 | 95.6 | 8.58 | 183.8 | ||
| All | 57.7 | 9.8 | 33.0 | 95.3 | 8.54 | 181.3 | ||
| EDITION JP2 (Terauchi et al24) 6 month |
Basal insulin + OAD | Gla-300 | 61.1 | 14.0 | 25.7 | 67.4 | 7.99 | 138.6 |
| Gla-100 | 60.5 | 13.9 | 24.8 | 65.9 | 8.06 | 133.2 | ||
| All | 60.8 | 14.0 | 25.3 | 66.7 | 8.02 | 136.8 | ||
| T1DM | ||||||||
| EDITION 4 (Home et al39) 6 month |
Basal insulin + mealtime insulin | Gla-300 | 46.4 | 20.5 | 27.6 | 81.9 | 8.11 | 185.9 |
| Gla-100 | 48.2 | 21.4 | 27.6 | 81.8 | 8.14 | 199.3 | ||
| All | 47.3 | 20.9 | 27.6 | 81.9 | 8.13 | 192.6 | ||
| EDITION JP1 (Matsuhisa et al40) 6 month |
Basal insulin + mealtime insulin | Gla-300 | 44.1 | 12.2 | 23.8 | 63.9 | 8.06 | NR |
| Gla-100 | 46.3 | 13.9 | 23.2 | 61.0 | 8.07 | NR | ||
| All | 45.2 | 13.0 | 23.5 | 62.5 | 8.07 | NR | ||
Abbreviations: Gla-100, insulin glargine 100 U/mL; Gla-300, insulin glargine 300 U/mL; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; OAD, oral antidiabetic drugs; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.